Keros Therapeutics approved a common-stock repurchase program of up to $5 million after receiving a $20 million development milestone from Takeda. The authorization matters because Keros said its cash and cash equivalents, adjusted for both items, should fund operating expenses and capital expenditures into the second half of 2028.

Key Highlights

  • Keros Therapeutics had cash and cash equivalents of $257.6 million as of June 30, 2026.
  • Management may repurchase common stock in the open market or through other lawful methods.
  • Keros Therapeutics approved a common-stock repurchase program authorizing management to buy up to $5 million of outstanding shares.
  • Repurchases may occur through open-market purchases or other methods permitted under applicable state and federal securities laws.

Keros Therapeutics, Inc. (NASDAQ: KROS) approved a common-stock repurchase program of up to $5 million, giving management authority to buy outstanding shares.

$5 Million Buyback Terms Keros’

board approved the program, which permits repurchases from time to time through open-market purchases or other methods allowed under applicable state and federal securities laws. The timing and size of any transaction will depend on the common stock’s market price, broader market and economic conditions, contractual limits and other considerations. Keros may change, suspend or end the program at any time. The authorization does not require the company to repurchase any specified dollar amount or number of shares. reported cash and cash equivalents of $257.6 million as of June 30, 2026.